ClinicalTrials.gg
CompletedNCT00424554Updated Jun 7, 2017Results posted

Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

A Phase 2 interventional study of temozolomide in Glioma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2006, registered Jan 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Enrollment
57th of 104
40 · median 41
Started
2006
with 2 others
Phase 2
51 of 112
4 open now
Registered
30th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 57th largest by enrollment of the 104 interventional ones that give a count, is one of 3 that started in 2006, is one of 51 in phase 2, and was the 30th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients with gliomas.

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of a brain tumor with high probability of being a glioma as detected by Magnetic Resonance Imaging (MRI). These would include newly diagnosed tumors or potentially recurrent gliomas.
  • No prior treatment for the tumor including chemotherapy or radiotherapy.
  • Amenable to surgery for or resection of the brain tumor. Surgically confirmed diagnosis of glioma (glioblastoma multiforme [GBM], anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA], astrocytoma [A] or oligodendroglioma [O]) will be

required for patients to be maintained in the study. Those not fulfilling this requirement will be discontinued and will be replaced.

  • Use of medically approved in fertile males and females.
  • Women with must have a negative urine or serum

pregnancy test (urinary excretion or serum level of beta-Human Chorionic

Gonadotropin [bHCG]) within 72 hours of randomization.

  • Performance Status score >= 70%.
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy.
  • Prior radiotherapy at the tumor site.
  • History of non-compliance to other therapies.
  • Inadequate haematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):

    • ≤1.5 x 10\^9/L;
    • ≤100 x 10\^9/L;
    • \<90 g/L;
    • Serum creatinine ≥1.5 times upper limit of laboratory normal;
    • Total serum ≥1.5 times upper limit of laboratory normal ();
    • (AST) or alanine aminotransferase (ALT) > 2.0 ULN;
    • Alkaline phosphatase of > 2.5 ULN.
  • Known [HIV] infection.
  • Known chronic or infection.
  • Any other serious medical condition according to the medical judgment of the physician prior to inclusion in the study.
  • Any medical condition, which could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Temozolomide treatment

    Drug: temozolomide

  • No intervention
    No treatment

Interventions

  • Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery. As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.

    Also known as: SCH 052365

06

What researchers measure

Primary outcomes

  1. MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery

    An experimental assay was developed to measure MGMT levels.

    Time frame: 14 days

Secondary outcomes

  1. Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities

    Grade 3 was defined as severe per Common Terminology Criteria for Adverse Events (CTCAE). Grade 4 was defined as life-threatening per CTCAE.

    Time frame: 12 months

  2. Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)

    An AE was defined as any event which was adverse, including what were commonly described as adverse or undesirable experiences, adverse events, adverse reactions, side effects, or death due to any cause associated with, or observed in conjunction with the use of a drug, biological product, or device in humans, whether or not considered related to the use of that product. Additionally, any event which was associated with, or observed in conjunction with product overdose whether accidental or intentional, or product abuse and/or withdrawal was also considered an AE.

    Time frame: 12 months

  3. Concentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor

    No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.

    Time frame: 14 days

  4. MGMT Activity in the Brain Tumor Tissues by Temozolomide Levels

    No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.

    Time frame: 14 days

07

Results

Posted Jun 29, 2011
Limitations and caveats
The assay developed to measure MGMT activity had high variability. The TMZ assay was unable to detect the low levels of the drug due to the relatively low dose and short half life of TMZ.

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide (TMZ)No Intervention
Started346
Completed346
Not completed00

Outcome measures

PrimaryMethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery

An experimental assay was developed to measure MGMT levels.

Time frame:
14 days
Reported as:
Mean · fmol/mg of proteins
MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery
fmol/mg of proteinsTemozolomide (TMZ)No Intervention
MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery333.7 ± 288.5105.1 ± 155
Statistical analysis
  • Temozolomide (TMZ) vs No Intervention · t-test, 2 sided · p = 0.09
SecondarySafety: Number of Participants Who Experienced Grade 3 or 4 Toxicities

Grade 3 was defined as severe per Common Terminology Criteria for Adverse Events (CTCAE). Grade 4 was defined as life-threatening per CTCAE.

Time frame:
12 months
Reported as:
Number · participants
Safety: Number of Participants Who Experienced Grade 3 or 4 Toxicities
participantsTemozolomide (TMZ)No Intervention
Grade 340
Grade 400
SecondaryTolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)

An AE was defined as any event which was adverse, including what were commonly described as adverse or undesirable experiences, adverse events, adverse reactions, side effects, or death due to any cause associated with, or observed in conjunction with the use of a drug, biological product, or device in humans, whether or not considered related to the use of that product. Additionally, any event which was associated with, or observed in conjunction with product overdose whether accidental or intentional, or product abuse and/or withdrawal was also considered an AE.

Time frame:
12 months
Reported as:
Number · participants
Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)
participantsTemozolomide (TMZ)No Intervention
Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)00
SecondaryConcentrations of Temozolomide in the Serum, Cerebrospinal Fluid, and Brain Tumor

No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.

Time frame:
14 days

No measurements were reported for this outcome.

SecondaryMGMT Activity in the Brain Tumor Tissues by Temozolomide Levels

No data available: at the time of tumor collection, the temozolomide levels were below the detection limits of the assay.

Time frame:
14 days

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide—0/34 (0%)13/34 (38.2%)
No Intervention—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTemozolomideNo Intervention
THROMBOCYTOPENIABlood and lymphatic system disorders0/341/6
DIARRHOEAGastrointestinal disorders0/341/6
PAINGeneral disorders0/341/6
URINARY TRACT INFECTIONInfections and infestations2/341/6
POSTOPERATIVE FEVERInjury, poisoning and procedural complications0/341/6
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/341/6
HYPERGLYCAEMIAMetabolism and nutrition disorders1/341/6
HYPOKALAEMIAMetabolism and nutrition disorders0/341/6
HYPONATRAEMIAMetabolism and nutrition disorders0/341/6
MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders1/341/6

Baseline characteristics

Age, Customized
Age, Customized(Participants)Temozolomide (TMZ)No InterventionTotal
Number34640
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide (TMZ)No InterventionTotal
Female17421
Male17219
Region of Enrollment
Region of Enrollment(participants)Temozolomide (TMZ)No InterventionTotal
Canada34640
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2006 to primary completion in Jan 2010, 39 months.

Results were first posted in Jun 2011, 1 year 5 months after primary completion.

Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2007
First posted
Jan 19, 2007
StartActual
Sep 26, 2006
Primary completionActual
Jan 11, 2010
CompletionActual
Feb 16, 2011
Results first posted
Jun 29, 2011
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424554
Responsible party
Sponsor
First posted
Jan 19, 2007
Start date
Sep 26, 2006
Primary completion
Jan 11, 2010
Completion
Feb 16, 2011
Results posted
Jun 29, 2011
Last update
Jun 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion